Fresh analysis reveals that people who stop using popular weight-loss injections like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who halt traditional diet and exercise regimens.
Published data in a leading health publication points out that while overweight individuals can lose a large proportion of their body weight while undergoing treatment, the mass comes back at an average rate of 0.8 kg per month after stopping.
"People buying these medications must be informed of the danger of quick rebound weight gain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to pre-treatment weight in about 18 months.
Analyzing Treatments
The research, which reviewed 37 of trials involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with other pills.
Scientists emphasize that individuals who lose weight through lifestyle changes alone usually have a more gradual weight regain—perhaps 100 grams monthly—post-intervention.
The Reason for the Quick Rebound
Experts believe the mode of action of the injections accounts for the amplified rebound.
These medications imitate a natural hormone called GLP-1, which helps regulate appetite.
"Long-term administration of GLP-1 concentrations far above than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is no longer kept in check, making excessive eating much more probable."
A Chronic Issue?
Medical guidelines advise the injections for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Professionals contend that, considering the high risk of relapse, the therapy should be considered life-long.
This perspective is supported by pharmaceutical companies, who note that the results "highlight the long-term character of excess weight," comparing it to managing diseases like diabetes.
User Experiences
People who have discontinued the medication describe a powerful return of appetite.
"It felt as if something that goes on and you become ravenous," described an individual.
This difficulty is worsened if users have not established lasting dietary or behavioural changes during treatment.
Growing Adoption
Recent estimates indicate that millions of adults in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Adoption is more common among women than men.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are effective tools for weight loss, they are not a standalone fix and maintained weight loss relies on ongoing behavioural management.